Yasumatsu Ryuji, Wakasaki Takahiro, Hashimoto Kazuki, Nakashima Koichiro, Manako Tomomi, Taura Masahiko, Matsuo Mioko, Nakagawa Takashi
Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Head Neck. 2019 Aug;41(8):2610-2618. doi: 10.1002/hed.25737. Epub 2019 Mar 5.
Predicting the response to treatment with nivolumab and the survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains a challenge. We investigated whether or not the neutrophil-to-lymphocyte ratio (NLR) kinetics could be used to predict the anticancer effect of nivolumab.
Forty-one patients with recurrent or metastatic HNSCC who had been treated with nivolumab were retrospectively analyzed. The NLR was calculated using pretreatment blood test results until the end of the treatment.
The posttreatment NLR was higher than the pretreatment value in 13 of 17 patients (76%) patients with progressive disease within the first 3 months, whereas the posttreatment NLR was lower than the pretreatment value in 10 of 11 patients (91%) with stable disease or partial response during the follow-up period.
Our results indicate that monitoring the NLR may aid in the earlier confirmation of treatment failure in patients with recurrent or metastatic HNSCC during nivolumab monotherapy.
预测复发或转移性头颈部鳞状细胞癌（HNSCC）患者接受纳武单抗治疗的反应及生存情况仍然是一项挑战。我们研究了中性粒细胞与淋巴细胞比值（NLR）动力学是否可用于预测纳武单抗的抗癌效果。
对41例接受纳武单抗治疗的复发或转移性HNSCC患者进行回顾性分析。使用治疗前血液检测结果计算NLR直至治疗结束。
在最初3个月内疾病进展的17例患者中，有13例（76%）治疗后的NLR高于治疗前值，而在随访期间病情稳定或部分缓解的11例患者中，有10例（91%）治疗后的NLR低于治疗前值。
我们的结果表明，监测NLR可能有助于在纳武单抗单药治疗期间更早地确认复发或转移性HNSCC患者的治疗失败情况。
